
LEUCOVORIN CALCIUM- leucovorin calcium tablet Leading Pharma, LLC

Leucovorin Calcium Tablets USP 5 mg, 10 mg, 15 mg and 25 mg Rx only

DESCRIPTION

Leucovorin Calcium Tablets contain either 5 mg, 10 mg, 15 mg or 25 mg leucovorin as the calcium salt of *N*-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6pteridinyl)methyl]amino]benzoyl]-*L*- glutamic acid and the inactive ingredients Colloidal Silicon Dioxide, Croscarmellose Sodium, Magnesium Stearate, Microcrystalline Cellulose and Pregelatinized Starch. This is equivalent to 5.4 mg, 10.8 mg, 16.21 mg or 27.01 mg of anhydrous leucovorin calcium.

Leucovorin is a water soluble form of reduced folate in the folate group; it is useful as an antidote to drugs which act as folic acid antagonists. These tablets are intended for oral administration only. The structural formula of leucovorin calcium is:



CLINICAL PHARMACOLOGY

Leucovorin is a racemic mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid. The biologically active compound of the mixture is the (-)-*L*-isomer, known as *Citrovorum factor*, or (-)-folinic acid. Leucovorin does *not* require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of "one-carbon" moieties. Following oral administration, leucovorin is rapidly absorbed and enters the general body pool of reduced folates. The increase in plasma and serum folate activity (determined microbiologically with *Lactobacillus casei*) seen after oral administration of leucovorin is predominantly due to 5-methyltetrahydrofolate.

Twenty normal men were given a single, oral 15-mg dose (7.5 mg/m2) of leucovorin calcium and serum folate concentrations were assayed with *L. casei*. Mean values observed (± one standard error) were:

a) Time to peak serum folate concentration: 1.72 ± 0.08 hours,

- b) Peak serum folate concentration achieved: 268 ± 18 ng/mL,
- c) Serum folate half-disappearance time: 3.5 hours.

Oral tablets yielded areas under the serum folate concentration-time curves (AUCs) that were 12% greater than equal amounts of leucovorin given intramuscularly and equal to the same amounts given intravenously.

Oral absorption of leucovorin is saturable at doses above 25 mg. The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg and 37% for 100 mg.

INDICATIONS AND USAGE

Leucovorin Calcium Tablets are indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists.

CONTRAINDICATIONS

Leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin B_{12} . A hematologic remission may occur while neurologic manifestations continue to progress.

WARNINGS

In the treatment of accidental overdosage of folic acid antagonists, leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate [MTX]) and leucovorin rescue increases, leucovorin's effectiveness in counteracting hematologic toxicity decreases.

Monitoring of the serum MTX concentration is essential in determining the optimal dose and duration of treatment with leucovorin.

Delayed MTX excretion may be caused by a third space fluid accumulation (i.e., ascites, pleural effusion), renal insufficiency, or inadequate hydration. Under such circumstances, higher doses of leucovorin or prolonged administration may be indicated. Doses higher than those recommended for oral use must be given intravenously.

Leucovorin may enhance the toxicity of fluorouracil. Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.¹ Concomitant granulocytopenia and fever were present in some but not all of the patients.

The concomitant use of leucovorin with trimethoprim-sulfamethoxazole for the acute treatment of *Pneumocystis carinii* pneumonia in patients with HIV infection was associated with increased rates of treatment failure and mortality in a placebo-controlled study.

PRECAUTIONS

General

Parenteral administration is preferable to oral dosing if there is a possibility that the patient may vomit or not absorb the leucovorin. Leucovorin has no effect on other established toxicities of MTX, such as the nephrotoxicity resulting from drug and/or metabolite precipitation in the kidney.

Drug Interactions

Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin, and primidone, and increase the frequency of seizures in susceptible pediatric patients.

Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydrofolate and, in humans, remain one to three orders of magnitude lower than the usual MTX concentrations following intrathecal administration.

However, high doses of leucovorin may reduce the efficacy of intrathecally administered MTX.

Leucovorin may enhance the toxicity of fluorouracil (see WARNINGS).

Pregnancy

Teratogenic Effects

Pregnancy

Animal reproduction studies have not been conducted with leucovorin. It is also not known whether leucovorin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Leucovorin should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when leucovorin is administered to a nursing mother.

Pediatric Use

See Drug Interactions subsection.

ADVERSE REACTIONS

CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1-800-FDA-1088 OR LEADING PHARMA, LLC AT 1-844-740-7500.

Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

OVERDOSAGE

Excessive amounts of leucovorin may nullify the chemotherapeutic effect of folic acid antagonists.

DOSAGE AND ADMINISTRATION

Leucovorin calcium tablets are intended for oral administration. Because absorption is saturable, oral administration of doses greater than 25 mg is not recommended.

Impaired Methotrexate Elimination or Inadvertent Overdosage

Leucovorin rescue should begin as soon as possible after an inadvertent overdosage and within 24 hours of methotrexate administration when there is delayed excretion (see WARNINGS). Leucovorin 15 mg (10 mg/m²) should be administered I.M., I.V., or P.O. every 6 hours until the serum methotrexate level is less than 10⁻⁸M. In the presence of gastrointestinal toxicity, nausea, or vomiting, leucovorin should be administered parenterally.

Serum creatinine and methotrexate levels should be determined at 24-hour intervals. If the 24-hour serum creatinine has increased 50% over baseline or if the 24-hour methotrexate level is greater than 5 x 10^{-6} M or the 48-hour level is greater than 9 x 10^{-7} M, the dose of leucovorin should be increased to 150 mg (100 mg/m²) I.V. every 3 hours until the methotrexate level is less than 10^{-8} M. Doses greater than 25 mg should be given parenterally (see CLINICAL PHARMACOLOGY).

Hydration (3 L/d) and urinary alkalinization with sodium bicarbonate should be employed concomitantly. The bicarbonate dose should be adjusted to maintain the urine pH at 7.0 or greater.

The recommended dose of leucovorin to counteract hematologic toxicity from folic acid antagonists with less affinity for mammalian dihydrofolate reductase than methotrexate (i.e., trimethoprim, pyrimethamine) is substantially less, and 5 to 15 mg of leucovorin per day has been recommended by some investigators.

Patients who experience delayed early methotrexate elimination are likely to develop reversible non-oliguric renal failure. In addition to appropriate leucovorin therapy, these patients require continuing hydration and urinary alkalinization, and close monitoring of fluid and electrolyte status, until the serum methotrexate level has fallen below 0.05 micromolar and the renal failure has resolved.

Some patients will have abnormalities in methotrexate elimination or renal function following methotrexate administration, which are significant but less severe. These abnormalities may or may not be associated with significant clinical toxicity. If significant clinical toxicity is observed, leucovorin rescue should be extended for an additional 24 hours (total 14 doses over 84 hours) in subsequent courses of therapy. The possibility that the patient is taking other medications which interact with methotrexate (e.g., medications which may interfere with methotrexate elimination or binding to serum albumin) should always be reconsidered when laboratory abnormalities or clinical toxicities are observed.

HOW SUPPLIED

Leucovorin Calcium Tablets USP

5 mg tablets are supplied as a white to off-white to pale yellow, round tablet; scored on one side and "LP" over "184" debossed on the other side; bottles of 30 (NDC 69315-184-03) and 100 (NDC 69315-184-01).

10 mg tablets are supplied as a white to off-white to pale yellow, round tablet; scored on one side and "LP" over "185" debossed on the other side; bottles of 12 (NDC 69315-185-12) and 24 (NDC 69315-185-24).

15 mg tablets are supplied as a white to off-white to pale yellow, round tablet; scored on one side and "LP" over " 186" debossed on the other side; bottles of 24 (NDC 69315-186-24).

25 mg tablets are supplied as a white to off-white to pale yellow, round tablet; scored on one side and "LP" over " 187" debossed on the other side; bottles of 25 (NDC 69315-187-25).

Store at 15° to 25°C (59° to 77°F). Protect from light and moisture.

REFERENCES

- 1. Grem JL, Shoemaker DD, Petrelli NJ, Douglas HO Jr. Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma. *Cancer Treat Rep.*1987;71:1122.
- Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapsefree survival in patients with osteosarcoma of the extremity. *N Engl J Med.*1986;314:1600-1606.

Rx only

Manufactured and Distributed by:

Leading Pharma, LLC

Fairfield, NJ 07004, USA

Rev.02 11/21

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL













_									
	COVORI		JM						
Ρ	roduct Infor	mation							
Р	roduct Type		HUMAN PRESCRIPTION DRUG	ltem	Code (Source)	N	DC:6	9315-184
	oute of Admini	istration	ORAL			,			
A	ctive Ingredi	ient/Active	Moiety						
		Ingr	edient Name		B	asis of	Streng	Jth	Strength
			R1R4C0P4) (LEUCOVORIN - UNII:Q5	7319DVL	P) LE	UCOVORI	N		5 mg
In	active Ingre	dients							
			Ingredient Name					Str	ength
	LICON DIOXIDE	-							
	ROSCARMELLOS								
	AGNESIUM STEA								
			J) E (UNII: OP1R32D61U)						
Pı	roduct Chara	acteristics							
Co	olor v	hite (White to o	ff-white to pale yellow)		Scor	e		2	pieces
Sł	nape R	OUND			Size		7mm		mm
Fla	avor				Impr	int Code	e	L	P;184
Co	ontains								
Pa	ackaging								
#	ltem Code	Pa	ckage Description	Mar	keting Date		Mar		ing End ate
1	NDC:69315-184- 03	30 in 1 BOTTL Product	E; Type 0: Not a Combination	11/16/2	020				
2	NDC:69315-184- 01	100 in 1 BOTT Product	LE; Type 0: Not a Combination	11/16/2	020				
Μ	larketing	Informat	ion						
	Marketing Category	Applica	tion Number or Monograph Citation	Ma	arketin Dat	g Start e	Ма		ting End ate
AN	DA	ANDA21392	9	11/16	6/2020				

LEUCOVORIN CALCIUM

leucovorin calcium tablet

	mation					
Product Type		HUMAN PRESCRIPTION DRUG	Item Co	ode (Source)	NDC:6	59315-185
Route of Admin	istration	ORAL				
Active Ingred	ient/Active	Moiety				
Ingredient Name Basis				Basis of S	Strength	Strengt
LEUCOVORIN CAL	CIUM (UNII: RPF	R1R4C0P4) (LEUCOVORIN - UNII:Q5	73I9DVLP)	LEUCOVORIN	N	10 mg
Inactive Ingre	dients					
		Ingredient Name			St	rength
SILICON DIOXIDE	(UNII: ETJ7Z6XB	U4)				
CROSCARMELLOS	E SODIUM (UN	II: M28OL1HH48)				
MAGNESIUM STEA						
STARCH, CORN (U		•				
MICROCRYSTALLI	NE CELLULOSI	(UNII: OP1R32D61U)				
Product Chara	atoriatica					
Product Char						
		ff white to pale vellow)		6.00 #0	-	Piecos
Color v	vhite (White to o	ff-white to pale yellow)		Score		2 pieces
Color v Shape F		ff-white to pale yellow)		Size	ç	9mm
Color v Shape F Flavor	vhite (White to o	ff-white to pale yellow)			ç	
Color v Shape F	vhite (White to o	ff-white to pale yellow)		Size	ç	9mm
Color v Shape F Flavor	vhite (White to o	ff-white to pale yellow)		Size	ç	9mm
Color v Shape F Flavor Contains	vhite (White to o	ff-white to pale yellow)		Size	ç	9mm
Color v Shape F Flavor Contains Packaging	vhite (White to o	ff-white to pale yellow)	Marke	Size Imprint Code	e L Market	9mm _P;185 ting End
Color v Shape F Flavor Contains Packaging # Item Code	vhite (White to o ROUND Pac		Marke	Size Imprint Code ting Start Date	e L Market	9mm _P;185
Color v Shape F Flavor Contains Packaging # Item Code 1 NDC:60315-185- 12	Pac 12 in 1 BOTTL Product	ckage Description	Marke [Size Imprint Code ting Start Date	e L Market	9mm _P;185 ting End
Color v Shape F Flavor Contains P Packaging # Item Code 1 NDC:69315-185- 12 NDC:69315-185-	Pac 24 in 1 BOTTL 24 in 1 BOTTL 24 in 1 BOTTL	Ckage Description E; Type 0: Not a Combination	Marke [11/16/2024	Size Imprint Code ting Start Date	e L Market	9mm _P;185 ting End
Color v Shape F Flavor Contains PCKaging Item Code I NDC:69315-185- 12 2 NDC:69315-185- 24	Pac ROUND 12 in 1 BOTTL Product 24 in 1 BOTTL Product	Ckage Description E; Type 0: Not a Combination E; Type 0: Not a Combination	Marke [11/16/2024	Size Imprint Code ting Start Date	e L Market	9mm _P;185 ting End
Color v Shape F Flavor Contains Packaging # Item Code 1 NDC:69315-185- 2 NDC:69315-185-	Pac Pac 12 in 1 BOTTL Product 24 in 1 BOTTL Product Informat	Ckage Description E; Type 0: Not a Combination E; Type 0: Not a Combination	Marke [11/16/2024 11/16/2024	Size Imprint Code ting Start Date	e L Market D	9mm P;185 ting End

LEUCOVORIN CALCIUM leucovorin calcium tablet						
Product Information						
Product Type	HUMAN PRESCRIPTION DRUG	ltem Code (Source)	NDC:69315-186			

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEUCOVORIN CALCIUM (UNII: RPRIRACOPA) (LEUCOVORIN - UNII:Q57319DVLP) LEUCOVORIN 15 mg Inactive Ingredients Inactive Ingredients Ingredient Name Strength Microcret colspan="2">Color White (Mhite to off-white to pale yellow) Score 2 pieces Shape ROUND Size 7mm Flavor Color white (Mhite to off-white to pale yellow) Score 2 pieces Shape ROUND Size 7mm Flavor Imprint Code LP:186 Colspan="2">Strength Marketing Start	of Adm	ninist	ration	ORAL					
Ingredient Name Basis of Strength Strength LEUCOVORIN CALCIUM (UNII: RPRIR4COP4) (LEUCOVORIN - UNII:Q573)9DVLP) LEUCOVORIN 15 mg Inactive Ingredients Ingredient Name Strength Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ72 6XBU4) Strength Strength CROSCARMELLOSE SODIUM (UNII: M280L1HH48) MAGNESIUM STEARATE (UNII: 70097M6130) Imachie Name Imachie Name STARCH, CORN (UNII: 08232NY35)) MICROCRYSTALLINE CELLULOSE (UNII: 0P1R32D61U) Imachie Name Imachie Name Product Characteristics Score 2 pieces Shape ROUND Size 7mm Flavor Imprint Code LP;186 Contains V Size 7mm Packaging Package Description Marketing Start Marketing End Date 1 NDC:69315-186 24 in 1 BOTTLE; Type 0: Not a Combination 11/16/2020 Imprint Code Marketing Application Number or Monograph Marketing Start Marketing End Date									
LEUCOVORIN CALCIUM (UNII: RPR1R4C0P4) (LEUCOVORIN - UNII:Q573I9DVLP) LEUCOVORIN 15 mg Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ726XBU4) CROSCARMELLOSE SODIUM (UNII: M280L1HH48) MAGNESIUM STEARATE (UNII: 70097M6130) STARCH, CORN (UNII: 08232NY35)) STARCH, CORN (UNII: 08232NY35)) MICROCRYSTALLINE CELLULOSE (UNII: 0P1R32D61U) Score 2 pieces Shape ROUND Score 2 pieces Shape Packaging # tem Code Package Description Marketing Start Marketing End Date NDC:69315-186 24 in 1 BOTTLE; Type 0: Not a Combination 11/16/2020 11/16/2020 V Marketing Start Marketing End Date	Ingre	edieı	nt/Active	Moiety					
Ingredients Ingredient Name Strength Strength Strength Strength Strength Strength Strength GoscarmeLLOSE SoDIUM (UNII: ETJ726XBU4) CoscarmeLLOSE SoDIUM (UNII: C0097M6I30) StarCH, CORN (UNII: 00937M6I30) StarCH, CORN (UNII: 00932NY35)) MICROCRYSTALLINE CELLULOSE (UNII: 0P1R32D61U) Score 2 pieces Shape ROUND Score 2 pieces Shape ROUND Size 7mm Imprint Code LP;186 Cotar Marketing End Date Product Product Product LP;186 Cotar Marketing End Date Product Product Product Product Product Product Product			Ingr	edient Name			Basis of S	Strength	Strength
Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) CROSCARMELLOSE SODIUM (UNII: M280L1HH48) MAGNESIUM STEARATE (UNII: 70097M6I30) STARCH, CORN (UNII: 00232NY35)) STARCH, CORN (UNII: 00232NY35)) STARCH, CORN (UNII: 00232NY35)) MICROCRYSTALLINE CELLULOSE (UNII: 0P1R32D61U) Score 2 pieces Stremistics Corta retristics 2 pieces Size 7mm Flavor Size 7mm Flavor Imprint Code LP;186 Size 7mm Flavor Imprint Code LP;186 Package Description Marketing Start Date Marketing End Date NDC:69315-18- 24 in 1 BOTTLE; Type 0: Not a Combination 11/16/2020 L Store Start Date Marketing End Date Marketing Celluluit Store Start Date Store Start Date Store Start Date	ORIN C		UM (UNII: RPF	R1R4C0P4) (LEUC	ovorin - Unii:Q5	73I9DVLP)	LEUCOVORIN	J	15 mg
Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) CONDIOXIDE (UNII: 2026XBU4) CONDIOXIDE (UNII: 70097M6I30) STARCH, CORN (UNII: 00232NY3S)) STARCH, CORN (UNII: 00232NY3S)) STARCH, CORN (UNII: 02232NY3S)) Starch (UNII: 0232NY3S)) Starch (UNII: 0232NY3S)) Starch (UNII: 0232NY3S)) Mite (White to off-white to pale yellow) Score 2 pieces Shape ROUN Size 7mm Protuct Characteristics Store Size 7mm Imprint Code LP;186 Protuce Size Store Size 7mm Leven LP;186 Product Imprint Code LP;186 NDC:69315-18- 24 in 1 BOTTLE; Type 0: Not a Combination 11/16/2020 L L Marketing Start Marketing End Marketing Category Application Number or Monograph Marketing Start Mar									
SILCON DIOXIDE (UNII: ETJ726XBU4) Image: Sol UM (UNII: M280L1HH48) MAGNESIUM STEARATE (UNII: 70097M6I30) Image: Sol UM (UNII: M280L1HH48) STARCH, CORN (UNII: 08232NY3S)) Image: Sol UM (UNII: 08232NY3S) MICROCRYSTALLINE CELLULOSE (UNII: 0P1R32D61U) Image: Sol UM (UNII: 08232NY3S) VIENCE Vience VIENCE Vien	ve Ing	gredi	ients						
CROSCARMELLOSE SODIUM (UNII: M280L1HH48)Magnesium STEARATE (UNII: 70097M6I30)STARCH, CORN (UNII: 08232NY3S))MICROCRYSTALLINE CELLULOSE (UNII: 0P1R32D61U)Socre2 piecesSize7Mite (White to off-white to pale yellow)Size2 piecesSize7Imprint Code2 piecesSize7Mite (White to off-white to pale yellow)Size7Mite (White to off-white to pale yellow)Size7MIC Colspan="4">Marketing StartMarketing End DatePolspan="4">Package DescriptionMarketing StartMarketing End DateMarketing StartApplication Number or Monograph CitationMarketing StartMarketing End Date				Ingredient	Name			St	rength
MagNessium STEARATE (UNII: 70097M6I30) Image: Starc H, CORN (UNII: 08232NY35)) Image: Starc H, CORN (UNII: 08232NY35)) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) Image: Starc H, CORN (UNII: OP1R32D61U) Image: Starc H, CORN (UNII: OP1R32D61U) Product Charteristics Score 2 pieces ROUND Size 7mm Fiavor OUND Size 7mm Imprint Code 1 Product Charteristics Stare ROUND Size 7mm Imprint Code 1		DE (UI	NII: ETJ7Z6XB	U4)					
STARCH, CORN (UNII: 08232NY3S)) Image: Starch and St	ARMELL	OSE S	SODIUM (UN	II: M28OL1HH48)					
Nickocrystalling Cellulose (UNII: OP1R32D61U) Imprint Code Product Characteristics Score 2 pieces Color white (White to off-white to pale yellow) Score 2 pieces ROUND Size 7mm Fiavor Imprint Code LP;186 Contains Imprint Code LP;186 Vertice Vertice Marketing End Marketing Librornation 11/16/2020 Vertice Marketing End Product Vertice	SIUM ST	TEARA	TE (UNII: 70	097M6I30)					
Product Characteristics Score 2 pieces Shape ROUND Size 7mm Flavor Imprint Code LP;186 Vortains Marketing Start Marketing End Date Model Package Description Marketing Start Date Marketing End Date Model Package Description Marketing Start Date Marketing End Date Marketing Start Application Number or Monograph Citation Marketing Start Date Marketing End Date	, CORN	(UNII:	08232NY35])					
Color white (White to off-white to pale yellow) Score 2 pieces Shape RUND Size 7mm Harrow Imprint Code P;186 Contains P Marketing End Date Marketing End Date MDC: 69315-186 24 in 1 BOTTLE; Type 0: Not a Combination Product Marketing Start Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Marketing End Date	RYSTA	LLINE	CELLULOSE	UNII: OP1R32D	61U)				
Color white (White to off-white to pale yellow) Score 2 pieces Shape RUND Size 7mm Harrow Imprint Code P;186 Contains P Marketing End Date Marketing End Date MDC: 69315-186 24 in 1 BOTTLE; Type 0: Not a Combination Product Marketing Start Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Marketing End Date									
Shape ROUND Size 7mm Flavor Imprint Code LP:186 Contains Imprint Code LP:186 Flavor Marketing Start Marketing End Date Marketing Category 24 in 1 BOTTLE; Type 0: Not a Combination Product 11/16/2020 Marketing Start Date Marketing End Date	ct Ch	arac	teristics						
Flavor Imprint Code LP;186 Contains Imprint Code LP;186 Packaging Marketing Start Marketing End # Item Code Package Description Marketing Start Marketing End 1 NDC:69315-186- 24 24 in 1 BOTTLE; Type 0: Not a Combination Product 11/16/2020 Imprint Code Imprint Code Marketing Code Application Number or Monograph Citation Marketing Start Date Marketing End Date	Color white (White to off-white to pale yellow)				Score	2	2 pieces		
Image: Second and Secon	Shape ROUND				Size	7	/mm		
Marketing Start Date Marketing End Date # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69315-186- 24 24 in 1 BOTTLE; Type 0: Not a Combination Product 11/16/2020 11/16/2020 Marketing End Date Marketing End Date Marketing Start Date	Flavor Imprint Code)	LP;186				
Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69315-186- 24 24 in 1 BOTTLE; Type 0: Not a Combination Product 11/16/2020 11/16/2020 Marketing Treation Marketing Start Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date	ns								
Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69315-186- 24 24 in 1 BOTTLE; Type 0: Not a Combination Product 11/16/2020 11/16/2020 Marketing Treation Marketing Start Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date									
Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69315-186- 24 24 in 1 BOTTLE; Type 0: Not a Combination Product 11/16/2020 11/16/2020 Marketing Treation Marketing Start Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date	_								
# Item Code Package Description Date Date 1 NDC:69315-186- 24 24 in 1 BOTTLE; Type 0: Not a Combination Product 11/16/2020 11/16/2020 Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date	ging								
Product II/10/2020 Marketing Information Application Number or Monograph Citation Marketing Category Application Number or Monograph Date	m Cod	le	Pao	kage Descri	ption				-
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date	59315-1			E; Type 0: Not a	Combination	11/16/202	0		
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date									
Category Citation Date Date	etin	g In	format	ion					
			Applicat			Mar			-
ANDA ANDA213929 11/16/2020			ANDA21392	9		11/16/2	2020		
LEUCOVORIN CALCIUM	ονο	RIN	CALCII	ЛМ					
	ovo	RIN	CALCIU	ЛМ					

leucovorin calcium tablet

Product Information HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:69315-187 Route of Administration ORAL VICCOUNT VICCOUNT VICCOUNT

Active Ingredient/Active Moiety	
Ingredient Name	

Basis of Strength Strength

In	active Ingr	edients				
		Ingredient Name			S	trength
SI		(UNII: ETJ7Z6XBU4)				
CR	ROSCARMELLO	SE SODIUM (UNII: M28OL1HH48)				
M	AGNESIUM STE	ARATE (UNII: 70097M6I30)				
ST	ARCH, CORN (UNII: O8232NY3SJ)				
МІ	CROCRYSTALL	INE CELLULOSE (UNII: OP1R32D61U)				
Pı	roduct Cha	racteristics				
Со	olor	white (White to off-white to pale yellow)		Score		2 pieces
Sh	аре	ROUND		Size		9mm
Fla	avor			Imprint Code	1	LP;187
Co	ontains					
Pa	ackaging					
#	ltem Code	Package Description		eting Start Date		eting Enc Date
1	NDC:69315-187 25	 25 in 1 BOTTLE; Type 0: Not a Combination Product 	11/16/202	20		
	arketing	Information				
М	arketing	Application Number or Monograp	h Mar	kating Ctart	Mari	ating Fr
Μ		Application Number or Monograp	n Mar	keting Start	Mark	ceting End
M	Marketing Category	Citation		Date		Date

Labeler - Leading Pharma, LLC (079575060)

Establishment							
Name	Address	ID/FEI	Business Operations				
Leading Pharma, LLC		079575060	MANUFACTURE(69315-184, 69315-185, 69315-186, 69315-187)				

Revised: 9/2023

Leading Pharma, LLC